Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A1 | P13866 | 1/20 | 0.33 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.30 |
| ▸ | MAOA | P21397 | 2/20 | 0.30 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL498218 | 0.85 | KCNN4 (0.32) | SCN9AGABRG2GABRB3GABRA5KCNH2 | |
| SCHEMBL2770816 | 0.85 | POLB (0.33) | HCAR1POLBTXNRD1ALDH1A1MAOA | |
| SCHEMBL2130270 | 0.79 | NR1H4 (0.45) | GABRG2GABRB3GABRA5KCNH2TXNRD1 | |
| SCHEMBL497775 | 0.75 | NR1H4 (0.41) | SCN9A | |
| SCHEMBL27761420 | 0.74 | NR1H4 (0.36) | SCN9A | |
| SCHEMBL498230 | 0.74 | MBOAT4 (0.32) | — | |
| SCHEMBL497639 | 0.73 | KCNN4 (0.40) | SLC5A1SLC5A2SCN9AHCAR1ALDH1A1 | |
| SCHEMBL2128494 | 0.72 | NR1H4 (0.43) | MAOA | |
| SCHEMBL27761419 | 0.71 | NR1H4 (0.38) | SCN9AKCNN4 | |
| SCHEMBL2770997 | 0.69 | NR1H4 (0.33) | SCN9AHCAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106077-B2 | Compounds and methods for modulating FXR | ELI LILLY AND COMPANY (US) | 2012-01-31 | — | — | US | disclosed |
| EP-2029558-B1 | COMPOUNDS AND METHODS FOR MODULATING FXR | LILLY CO ELI (US) | 2010-03-10 | — | — | EP | disclosed |
| CN-101448798-A | Compounds and methods for modulating FXR | LILLY CO ELI (US) | 2009-06-03 | — | — | CN | disclosed |
| US-20090093524-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2009-04-09 | — | — | US | disclosed |
| EP-2029558-A2 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007140174-A2 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093524-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | NR1H4, SLC10A1, FXR1 | SLC5A1 264/4885SLC5A2 321/4885SCN9A 3726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.